BeiGene Ltd (BGNE)
139.02
+8.08
(+6.17%)
USD |
NASDAQ |
Apr 23, 16:00
139.02
0.00 (0.00%)
After-Hours: 20:00
BeiGene Cash from Financing (TTM): 416.48M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 416.48M |
September 30, 2023 | -40.94M |
June 30, 2023 | 156.09M |
March 31, 2023 | -27.57M |
December 31, 2022 | -18.97M |
September 30, 2022 | 3.476B |
June 30, 2022 | 3.465B |
March 31, 2022 | 3.518B |
December 31, 2021 | 3.637B |
September 30, 2021 | 577.92M |
June 30, 2021 | 2.463B |
March 31, 2021 | 2.508B |
December 31, 2020 | 5.203B |
September 30, 2020 | 4.879B |
June 30, 2020 | 2.910B |
March 31, 2020 | 2.845B |
December 31, 2019 | 85.68M |
Date | Value |
---|---|
September 30, 2019 | 92.28M |
June 30, 2019 | 938.40M |
March 31, 2019 | 969.60M |
December 31, 2018 | 1.691B |
September 30, 2018 | 1.685B |
June 30, 2018 | 1.153B |
March 31, 2018 | 1.252B |
December 31, 2017 | 490.36M |
September 30, 2017 | 686.00M |
June 30, 2017 | 353.93M |
March 31, 2017 | 213.39M |
December 31, 2016 | 380.90M |
September 30, 2016 | 182.09M |
June 30, 2016 | 180.82M |
March 31, 2016 | 273.25M |
December 31, 2015 | 103.20M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-40.94M
Minimum
Sep 2023
5.203B
Maximum
Dec 2020
1.952B
Average
2.463B
Median
Jun 2021
Cash from Financing (TTM) Benchmarks
Theravance Biopharma Inc | -198.93M |
LumiraDx Ltd | 58.14M |
ASLAN Pharmaceuticals Ltd | -- |
Zai Lab Ltd | -6.433M |
Legend Biotech Corp | 791.49M |